Library

Alopecia encompasses various forms of hair loss, including autoimmune conditions like Alopecia Areata, genetic patterns like Androgenetic Alopecia, and temporary issues like Telogen Effluvium. Treatment options vary based on the type and may include medications and topical solutions like TrichoSol™, which enhances hair growth through specialized technology. Personalized medicine and compounding pharmacies are crucial in tailoring treatments to individual needs. This study evaluates the safety and efficacy of TrichoSol™ with multiple active ingredients to support its use in compounded alopecia therapies. For this purpose, compatibility studies were performed using stability-indicating methods to determine the beyond-use dates (BUDs) of compounded formulations within TrichoSol™. The results demonstrates that: metronidazole, caffeine, and triamcinolone are stable for 180 days; 17-a-estradiol is stable for 150 days, while spironolactone lasts 120 days; clobetasol propionate is stable for 90 days, and both finasteride, tretinoin, and melatonin are stable for 60 days in TrichoSol™, all at room temperature. Therefore, TrichoSol™ offers a practical compounding vehicle for these active pharmaceutical ingredients in a liquid topical formulation.

Hardshell capsules are commonly used in individualized formulations due to their flexibility and convenience. However, the choice of excipients is crucial to maintain the stability, compatibility, and efficacy of the active pharmaceutical ingredient (API). While excipients are generally inert, they significantly impact the manufacturing process, stability, and dissolution of APIs. Fagron’s DiluCap® line offers six functional excipients designed to optimize capsule formulations. This study assessed the dissolution profiles of hard-shell capsules containing various APIs: minoxidil (1 mg and 2.5 mg) in DiluCap® SLD, finasteride (1 mg and 5 mg) in DiluCap® PSD, minoxidil + finasteride (2.5 mg + 1 mg) in DiluCap® SLD, melatonin (2 mg) in DiluCap® SR, and naltrexone (1.5 mg) in DiluCap® SR. Dissolution tests were performed under gastrointestinal-simulating conditions. Minoxidil and finasteride capsules showed rapid dissolution, while melatonin and naltrexone capsules exhibited controlled release. These results demonstrate the versatility of DiluCap® excipients, highlighting their suitability for different applications in compounding pharmacies. The study emphasizes the importance of selecting the right excipients to ensure API performance, enhance bioavailability, and optimize the compounding process.

This study assessed the compatibility of six APIs (17-a-estradiol, betamethasone, finasteride, melatonin, prednicarbate, spironolactone) in TrichoFoam™, a foaming vehicle for alopecia treatment. Stability tests confirmed API effectiveness, suggesting TrichoFoam™ as a promising, personalized, and patient-friendly platform to improve treatment adherence and outcomes in alopecia management.

This study evaluates the compatibility of three formulations for androgenetic alopecia (AGA) treatment with the ready-to-use Fagron Advanced Derma vehicle Espumil™. The formulations, including minoxidil combinations with caffeine, 17-alpha-estradiol, and tretinoin, demonstrated beyond-use dates over 90 days. The findings suggest Espumil™ is a viable option for personalized, effective AGA treatments.

A study on Cleoderm™, a semi-solid vehicle for acne treatment, evaluated its effectiveness and acceptance in a split-face trial of 10 patients. Results showed Cleoderm™ outperformed a commercial vehicle base in 80% of cases, offering better outcomes and comfort. Compounded formulations may enhance personalized acne therapy.

Pharmaceutical compounding companies face challenges in scaling operations to meet patient needs, particularly due to the 14-day sterility test delaying personalized medications. Fagron Sterile Services (FSS) addresses these issues by incorporating new technologies, streamlining processes, and improving speed while maintaining safety and compliance.

This study assessed the physical, chemical, and microbiological stability of active pharmaceutical ingredients in TrichoSol™ for alopecia treatments. HPLC and antimicrobial testing determined beyond-use dates (BUDs) ranging from 90 to 180 days for various compounds, including cetirizine hydrochloride, dutasteride, hydrocortisone acetate, nicotinamide, progesterone, and pyridoxine hydrochloride.

This study evaluated the compatibility and stability of APIs in Cleoderm™ using HPLC and forced degradation studies. Adapalene, dapsone, and hydroquinone formulations showed 180-day beyond-use dates with no physical or chemical changes. Microbiological tests confirmed preservative efficacy, highlighting Cleoderm™ as a reliable vehicle for dermatological preparations, particularly for acne and inflammatory dermatoses.

A new compounding topical solution (CTS) was developed for personalized alopecia treatment. It showed clinical tolerability with no irritation or phototoxic effects. CTS is compatible with active ingredients and may promote hair growth by enhancing fibroblast proliferation and gene expression. It offers a potential alternative or complement for alopecia management.

A new Compounding Cream Base (CCB) was developed as a topical acne treatment. It showed clinical tolerability with no irritation, comedogenic, or sensitizing effects. CCB may reduce sebum, lipid oxidation, microbial growth, and inflammation. It is compatible with active ingredients, supporting personalized acne therapy in dermatology practices.